William Sellers Net Worth

William Sellers biography

William R. Sellers serves as Independent Director of the Company. Dr. Sellers is a Class II director who has served as a member of our Board of Directors since September 2019. Since 2017, Dr. Sellers has served as a Core Institute Member at the Broad Institute and a Professor of Medicine at the Dana-Farber Institute and Harvard Medical School where he is responsible for running a research group focused on translating genomic discoveries into new therapeutics. In 2019, Dr. Sellers co-founded Civetta Therapeutics where he serves as a member of the board of directors. Dr. Sellers also serves as a member of the scientific advisory board for several biopharmaceutical companies, including Ideaya Biosciences (NASDAQ: IDYA), Epidarex Capital, Servier Pharmaceuticals, and Astex Pharmaceuticals. Furthermore, he served as a member of the board of directors for Peloton Therapeutics from 2017 to 2019. Dr. Sellers previously served as Vice President / Global Head of Oncology at Novartis Institutes for BioMedical Research from 2005 to 2016 where he led preclinical drug discovery and early clinical development. Appointed by President Barack Obama, he also served as a member of the National Cancer Advisory Board from 2011 to 2016. He previously was an Associate Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School and an Associate Member of the Broad Institute. Dr. Sellers received his B.S. in biology from Georgetown University in 1982 and M.D. from the University of Massachusetts Medical School in 1986. He completed his internship and residency in internal medicine at the University of California San Francisco in 1989 and trained in medical oncology at the Dana-Farber Cancer Institute. Seller’s extensive business experience in oncology research and in the area of drug discovery and development qualify him to serve as a member of our Board of Directors.

What is the salary of William Sellers?

As the Independent Director of Bluebird bio Inc, the total compensation of William Sellers at Bluebird bio Inc is $751,484. There are 6 executives at Bluebird bio Inc getting paid more, with Nick Leschly having the highest compensation of $13,153,600.

How old is William Sellers?

William Sellers is 59, he's been the Independent Director of Bluebird bio Inc since 2019. There are 4 older and 18 younger executives at Bluebird bio Inc. The oldest executive at Bluebird bio Inc is Wendy Dixon, 64, who is the Independent Director.

What's William Sellers's mailing address?

William's mailing address filed with the SEC is 60 BINNEY STREET, , CAMBRIDGE, MA, 02142.

Insiders trading at Bluebird bio Inc

Over the last 11 years, insiders at Bluebird bio Inc have traded over $130,743,125 worth of Bluebird bio Inc stock and bought 6,469 units worth $399,874 . The most active insiders traders include Steven Gillis, John Maraganore e Robert I Tepper. On average, Bluebird bio Inc executives and independent directors trade stock every 8 days with the average trade being worth of $6,033. The most recent stock trade was executed by Thomas J Klima on 3 June 2024, trading 3,834 units of BLUE stock currently worth $3,719.

What does Bluebird bio Inc do?

we are leading the gene therapy revolution. our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing – providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. we have a lot of energy, and it’s not just the abundance of coffee that keeps us going. find out what sparks our excitement and inspires us every day.

Bluebird bio Inc executives and stock owners

Bluebird bio Inc executives and other stock owners filed with the SEC include:

• Nick Leschly,
  President, Chief Executive Officer, Director
• William Baird,
  Chief Financial Officer
• David Davidson,
  Chief Medical Officer
• Philip Gregory,
  Chief Scientific Officer
• Jason Cole,
  Chief Operating Officer and Legal Officer, Secretary
• Nick Leschly,
  Pres & Director
• William Sellers,
  Independent Director
• William D. Baird III,
  Principal Financial & Accounting Officer
• Daniel Lynch,
  Independent Chairman of the Board
• Jason F. Cole Esq.,
  Chief Strategy & Financial Officer
• Thomas J. Klima,
  Chief Commercial Officer & COO
• Mark Vachon,
  Independent Director
• David Schenkein,
  Independent Director
• Wendy Dixon,
  Independent Director
• John Agwunobi,
  Independent Director
• Ingrid Goldberg,
  VP, Investor Relations
• Denice Torres,
  Director
• Joanne Smith-Farrell,
  Chief Business Officer
• Alison Finger,
  Chief Commercial Officer
• Katy Burnett,
  Interim Principal Accounting Officer
• Richard Colvin M.D., Ph.D.,
  Chief Medical Officer
• Andrea Walton,
  Chief People Officer
• Katherine Edna Breedis C.F.A., CMT,
  Interim CFO, Principal Financial Officer & Principal Accounting Officer
• Anne-Virginie Eggimann M.Sc.,
  Chief Regulatory Officer
• Melissa Bonner,
  Sr. VP of Research
• Dr. Liviu Niculescu M.D., Ph.D.,
  Sr. VP of Global Medical Affairs
• Sarah Alspach,
  Chief Communications Officer
• Kathleen A. Wilkinson,
  Chief People Officer
• Elizabeth Pingpank,
  Director of Corp. Communications
• Helen C. Fu,
  Sr. VP, Gen. Counsel & Sec.
• Jessica Whitten,
  VP, Global Controller & Chief Accounting Officer
• Kasra Kasraian,
  Sr. VP of Technical Devel. & Operations
• Gina R. Consylman CPA,
  Chief Financial Officer
• Andrew Obenshain,
  Pres, CEO & Director
• John Maraganore,
  Director
• James Mandell,
  Director
• Susanna Gatti High,
  Chief Operating Officer
• Eric Sullivan,
  Principal Accounting Officer
• Andrew Obenshain,
  President and CEO
• Douglas Melton,
  
• Mary Lynne Hedley,
  Director
• Kory James Wentworth,
  Principal Accounting Officer
• Thomas J Klima,
  See Remarks
• Charlotte Jones Burton,
  
• Axel Polack,
  Director
• Geert Jan Mulder,
  Director
• Christopher Krawtschuk,
  Chief Financial Officer
• Mitchell H. Finer,
  Chief Scientific Officer
• James M. Detore,
  Chief Financial Officer
• Venture Fund Vii Lparch Ven...,
  
• Robert I Tepper,
  Director
• Rock Ventures Lptrv Gp, Llc...,
  
• Linda Bain,
  VP, Fin. & Business Operations
• Rock Ventures Lp Third Rock...,
  
• Jeffrey T. Walsh,
  Chief Strategy Officer
• Steven Gillis,
  Director
• Richard A. Paulson,
  
• Gina Consylman,
  Chief Financial Officer
• Anne Virginie Eggimann,
  Chief Regulatory Officer
• Jessica Whitten,
  Chief Accounting Officer
• Marcela V. Maus,
  Director
• Sarah Js Glickman,
  Director
• Ramy Ibrahim,
  Director
• Joseph Vittiglio,
  Chief Business & Legal Officer
• Richard A Colvin,
  Chief Medical Officer
• Najoh Tita Reid,
  
• Elisabeth Leiderman,
  
• Michael Cloonan,
  
• O. James Sterling,
  Chief Financial Officer